Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors

被引:7
|
作者
Wefel, Jeffrey S. [1 ]
Ryan, Charles J. [2 ]
Van, Julie [3 ]
Jackson, James C. [4 ]
Morgans, Alicia K. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA
[3] Brigham Young Univ, Provo, UT 84602 USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Dana Farber Canc Inst, Survivorship Program, 450 Brookline Ave,DA 09-930, Boston, MA 02215 USA
关键词
QUALITY-OF-LIFE; MINI-MENTAL-STATE; ACETATE PLUS PREDNISONE; DEPRIVATION THERAPY; ABIRATERONE ACETATE; ACTIVITIES QUESTIONNAIRE; INTERNATIONAL SOCIETY; GERIATRIC ASSESSMENT; ALZHEIMERS-DISEASE; INCREASED SURVIVAL;
D O I
10.1007/s40263-022-00913-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Preservation of cognitive function is an important outcome in oncology. Optimal patient management requires an understanding of cognitive effects of the disease and its treatment and an efficacious approach to assessment and management of cognitive dysfunction, including selection of treatments to minimize the risk of cognitive impairment. Awareness is increasing of the potentially detrimental effects of cancer-related cognitive dysfunction on functional independence and quality of life. Prostate cancer occurs most often in older men, who are more likely to develop cognitive dysfunction than younger individuals; this population may be particularly vulnerable to treatment-related cognitive disorders. Prompt identification of treatment-induced cognitive dysfunction is a crucial aspect of effective cancer management. We review the potential etiologies of cognitive decline in patients with prostate cancer, including the potential role of androgen receptor pathway inhibitors; commonly used tools for assessing cognitive function validated in metastatic castration-resistant prostate cancer and adopted in non-metastatic castration-resistant prostate cancer trials; and strategies for management of cognitive symptoms. Many methods are currently used to assess cognitive function. The prevalence and severity of cognitive dysfunction vary according to the instruments and criteria applied. Consensus on the definition of cognitive dysfunction and on the most appropriate approaches to quantify its extent and progression in patients treated for prostate cancer is lacking. Evidence-based guidance on the appropriate tools and time to assess cognitive function in patients with prostate cancer is required. Plain Language Summary Men with prostate cancer are usually elderly and may have other health conditions. Old age, poor health, and some medications can all affect a person's ability to think clearly, make sound judgments, remember things, and learn new information. These mental difficulties can make it hard for people to do day-to-day tasks such as shopping or making a meal, looking after themselves, or taking medications correctly. People may also have problems with friendships and relationships. Therefore, before a man starts treatment for prostate cancer, he and his doctor must consider the likelihood that his mental ability might be affected by the treatment in order to choose the most suitable treatment option. Initially, the doctor can use short screening tests, such as asking the patient to remember and repeat numbers or words, draw objects, name things in a picture, or complete a survey. If these tests show that the patient might be having mental difficulties, he may be invited for additional tests with a specialist, called a neuropsychologist. A patient with, or at risk of, mental difficulties will be offered a care plan, which might include one or more of the following: selecting or switching treatments to avoid side effects; using memory aids; treatment for pain, difficulty sleeping, depression, or other problems that might affect mental function; sessions with a specialist to improve mental ability and develop techniques to adapt to worsening mental function; physical exercise; and getting help from others with household tasks, personal care, or taking medications.
引用
收藏
页码:419 / 449
页数:31
相关论文
共 50 条
  • [31] Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies
    Vaz-Ferreira, Ana
    Tavares, Valeria
    de Melo, Ines Guerra
    Rodrigues, Patricia Rafaela
    Afonso, Ana
    Mauricio, Maria Joaquina
    Medeiros, Rui
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [32] Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis
    Matsukawa, Akihiro
    Yanagisawa, Takafumi
    Parizi, Mehdi Kardoust
    Laukhtina, Ekaterina
    Klemm, Jakob
    Fazekas, Tamas
    Mori, Keiichiro
    Kimura, Shoji
    Briganti, Alberto
    Ploussard, Guillaume
    Karakiewicz, Pierre I.
    Miki, Jun
    Kimura, Takahiro
    Rajwa, Pawel
    Shariat, Shahrokh F.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, : 298 - 308
  • [33] The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer
    Taniguchi, Hisanori
    Ikeda, Junichi
    Masuo, Yuki
    Kinoshita, Hidefumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [34] Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
    Menssouri, Naoual
    Poiraudeau, Loic
    Helissey, Carole
    Bigot, Ludovic
    Sabio, Jonathan
    Ibrahim, Tony
    Pobel, Cedric
    Nicotra, Claudio
    Ngo-Camus, Maud
    Lacroix, Ludovic
    Rouleau, Etienne
    Tselikas, Lambros
    Chauchereau, Anne
    Blanc-Durand, Felix
    Bernard-Tessier, Alice
    Patrikidou, Anna
    Naoun, Natacha
    Flippot, Ronan
    Colomba, Emeline
    Fuerea, Alina
    Albiges, Laurence
    Lavaud, Pernelle
    van de Wiel, Paul
    den Biezen, Eveline
    Wesseling-Rozendaal, Yvonne
    Ponce, Santiago
    Michiels, Stefan
    Massard, Christophe
    Gautheret, Daniel
    Barlesi, Fabrice
    Andre, Fabrice
    Besse, Benjamin
    Scoazec, Jean-Yves
    Friboulet, Luc
    Fizazi, Karim
    Loriot, Yohann
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4504 - 4517
  • [35] Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials
    Roviello, Giandomenico
    Sigala, Sandra
    Sandhu, Shahneen
    Bonetta, Alberto
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Bottini, Alberto
    Sternberg, Cora N.
    Fox, Stephen B.
    Generali, Daniele
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : 111 - 121
  • [36] Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
    Lavaud, Pernelle
    Dumont, Clement
    Thibault, Constance
    Albiges, Laurence
    Baciarello, Giulia
    Colomba, Emeline
    Flippot, Ronan
    Fuerea, Alina
    Loriot, Yohann
    Fizazi, Karim
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [37] Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)
    Liu, Yang
    Zhang, Hui-min
    Jiang, Yu
    Wen, Zhi
    Bao, Er-hao
    Huang, Jing
    Wang, Chong-jian
    Chen, Cai-xia
    Wang, Jia-hao
    Yang, Xue-song
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : 594 - 601.e2
  • [38] Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic
    Kitajima, Rei
    Miyamoto, Seiya
    Tenjin, Tomomi
    Ojima, Kazuaki
    Ogino, Shin
    Miyake, Nobumi
    Fujiwara, Keisuke
    Funamoto, Yasuyuki
    Arai, Jun
    Tsukahara, Sachiko
    Ito, Yukie
    Tadokoro, Masanori
    Anai, Kiriko
    Kaneda, Yasuhiro
    Yamaguchi, Noboru
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 36 (02) : 300 - 306
  • [39] Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials
    Jones, Craig
    Gray, Struan
    Brown, Michael
    Brown, Janet
    Mccloskey, Eugene
    Rai, Bhavan P.
    Clarke, Noel
    Sachdeva, Ashwin
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 993 - 1004
  • [40] An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
    Morgans, Alicia K.
    Hutson, Thomas
    Guan, Alice Kai Dan
    Garcia, David
    Zhou, Anna
    Drea, Edward
    Vogelzang, Nicholas J.
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)